ASH 2021 | DREAMM-5 sub-study: belamaf in combination with feladilimab in the treatment of R/R myeloma
In this video, Natalie Callander, MD, University of Wisconsin School of Medicine and Public Health, Madison, WI, presents some preliminary findings from a sub-study of the DREAMM-5 platform trial (NCT04126200), which analyzed the safety and efficacy of the antibody-drug conjugate belantamab mafodotin (belamaf) in combination with feladilimab, an inducible T-cell co-stimulatory agonist (aICOS) in patients with relapsed/refractory (R/R) myeloma. Dr Callander highlights some of the results of this sub-study, including the overall and partial response rates observed in patients. To conclude, Dr Callander compares some safety signals in this sub-study with those observed in the DREAMM-2 trial (NCT03525678), drawing focus on the incidence of keratopathy. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA, 2021.
